Shandong Jincheng Pharmaceutical (SHE:300233) unit Beijing Jincheng Tail Pharmaceutical obtained Good Manufacturing Practice compliance certification for its erythromycin lactobionate active pharmaceutical ingredient.
The approval was granted by Beijing drug regulators following an on-site inspection in late October 2025, according to a filing with the Shenzhen bourse.
The certification clears the way for domestic production and sales of the macrolide antibiotic.